Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1973 7
1974 9
1975 7
1976 28
1977 26
1978 33
1979 26
1980 29
1981 34
1982 33
1983 50
1984 39
1985 55
1986 52
1987 47
1988 49
1989 52
1990 50
1991 43
1992 50
1993 43
1994 62
1995 53
1996 56
1997 66
1998 43
1999 70
2000 60
2001 43
2002 55
2003 54
2004 59
2005 64
2006 64
2007 77
2008 85
2009 79
2010 85
2011 93
2012 84
2013 104
2014 95
2015 104
2016 85
2017 99
2018 86
2019 82
2020 83
2021 75
2022 77
2023 36

Text availability

Article attribute

Article type

Publication date

Search Results

2,684 results

Results by year

Filters applied: . Clear all
Page 1
Spatial and neighborhood-level correlates of lay naloxone reversal events and service availability.
Yi G, Dayton L, Uzzi M, Browne K, Konstantopoulos A, Latkin C. Yi G, et al. Int J Drug Policy. 2022 Aug;106:103739. doi: 10.1016/j.drugpo.2022.103739. Epub 2022 Jun 9. Int J Drug Policy. 2022. PMID: 35691087 Clinical Trial.
This study analyzes spatial and neighborhood correlates of free naloxone distribution sites as well as overdose and naloxone reversal events in Baltimore, Maryland, which has one of the highest overdose rates in the country. ...CONCLUSION: Study findings emphasize t …
This study analyzes spatial and neighborhood correlates of free naloxone distribution sites as well as overdose and naloxone r …
A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.
Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J, et al. Bracken MB, et al. N Engl J Med. 1990 May 17;322(20):1405-11. doi: 10.1056/NEJM199005173222001. N Engl J Med. 1990. PMID: 2278545 Free article. Clinical Trial.
Studies in animals indicate that methylprednisolone and naloxone are both potentially beneficial in acute spinal-cord injury, but whether any treatment is clinically effective remains uncertain. We evaluated the efficacy and safety of methylprednisolone and naloxone …
Studies in animals indicate that methylprednisolone and naloxone are both potentially beneficial in acute spinal-cord injury, but whe …
Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers.
Skulberg AK, Tylleskar I, Nilsen T, Skarra S, Salvesen Ø, Sand T, Loftsson T, Dale O. Skulberg AK, et al. Eur J Clin Pharmacol. 2018 Jul;74(7):873-883. doi: 10.1007/s00228-018-2443-3. Epub 2018 Mar 22. Eur J Clin Pharmacol. 2018. PMID: 29568976 Clinical Trial.
PURPOSE: This study aimed to develop a model for pharmacodynamic and pharmacokinetic studies of naloxone antagonism under steady-state opioid agonism and to compare a high-concentration/low-volume intranasal naloxone formulation 8 mg/ml to intramuscular 0.8 mg. ...I …
PURPOSE: This study aimed to develop a model for pharmacodynamic and pharmacokinetic studies of naloxone antagonism under steady-stat …
A randomized clinical trial of the effects of ultra-low-dose naloxone infusion on postoperative opioid requirements and recovery.
Xiao Y, Wu L, Zhou Q, Xiong W, Duan X, Huang X. Xiao Y, et al. Acta Anaesthesiol Scand. 2015 Oct;59(9):1194-203. doi: 10.1111/aas.12560. Epub 2015 Jun 4. Acta Anaesthesiol Scand. 2015. PMID: 26041316 Clinical Trial.
We hypothesized that naloxone prevents the acute opioid tolerance produced by a large dose of remifentanil, and reduces the incidence of opioid-induced side effects. ...RESULTS: Cumulative morphine consumption at 24 h after surgery was higher in the large-dose remifentanil …
We hypothesized that naloxone prevents the acute opioid tolerance produced by a large dose of remifentanil, and reduces the incidence …
Naloxone and nalmefene absorption delivered by hollow microneedles compared to intramuscular injection.
Papich MG, Narayan RJ. Papich MG, et al. Drug Deliv Transl Res. 2022 Feb;12(2):376-383. doi: 10.1007/s13346-021-01096-0. Epub 2021 Nov 24. Drug Deliv Transl Res. 2022. PMID: 34817831 Clinical Trial.
Naloxone and nalmefene were administered to seven research beagle dogs (mean weight approximately 12 kg) at doses of 0.04 mg/kg and 0.014 mg/kg for naloxone and nalmefene, respectively. ...We also observed that although the dose for naloxone was approximately …
Naloxone and nalmefene were administered to seven research beagle dogs (mean weight approximately 12 kg) at doses of 0.04 mg/kg and 0 …
Design and interpretation of opiate antagonist trials in dementia.
Tariot PN, Sunderland T, Murphy DL, Cohen MR, Welkowitz JA, Weingartner H, Newhouse PA, Cohen RM. Tariot PN, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(3-5):611-26. doi: 10.1016/0278-5846(86)90031-x. Prog Neuropsychopharmacol Biol Psychiatry. 1986. PMID: 3025928 Review.
The design of a multidose naloxone study of 12 dementia patients is discussed, with reference to the pharmacokinetics, pharmacodynamics, and specificity of naloxone as well as to the nature of the dependent measures selected for this study. ...These findings are con …
The design of a multidose naloxone study of 12 dementia patients is discussed, with reference to the pharmacokinetics, pharmacodynami …
[Randomized double-blind clinical trial of moderate dosage naloxone in acute moderate and severe traumatic brain injury].
Chen B, Liu YS. Chen B, et al. Hunan Yi Ke Da Xue Xue Bao. 2002 Feb 28;27(1):58-60. Hunan Yi Ke Da Xue Xue Bao. 2002. PMID: 12575238 Clinical Trial. Chinese.
Naloxone or saline placebo was intravenously given for 10 days. We followed up for at least 1 month. ...The mortalities of the naloxone group and the saline group were 0 and 5% respectively. After the one-month follow-up, Glasgow outcome scale and verbal function in …
Naloxone or saline placebo was intravenously given for 10 days. We followed up for at least 1 month. ...The mortalities of the nal …
Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.
Duke AN, Correia CJ, Walsh SL, Bigelow GE, Strain EC. Duke AN, et al. Psychopharmacology (Berl). 2010 Aug;211(3):303-12. doi: 10.1007/s00213-010-1898-4. Epub 2010 Jun 25. Psychopharmacology (Berl). 2010. PMID: 20577717 Free PMC article. Clinical Trial.
However, the addition of naloxone may not limit abuse potential of this medication when taken by individuals without opioid physical dependence. ...The addition of naloxone did not significantly alter the effects of buprenorphine. ...
However, the addition of naloxone may not limit abuse potential of this medication when taken by individuals without opioid physical …
Naloxone-ethanol interaction in experimental and clinical situations.
Nuotto E, Palva ES, Seppälä T. Nuotto E, et al. Acta Pharmacol Toxicol (Copenh). 1984 Apr;54(4):278-84. doi: 10.1111/j.1600-0773.1984.tb01931.x. Acta Pharmacol Toxicol (Copenh). 1984. PMID: 6375258 Clinical Trial.
In all trials, two successive intravenous injections of naloxone (0.4 and 2.0 mg) were given at an interval of 0.5-1.5 hours. ...Our results suggest that naloxone has no clinical significance in antagonizing ethanol intoxication. ...
In all trials, two successive intravenous injections of naloxone (0.4 and 2.0 mg) were given at an interval of 0.5-1.5 hours. ...Our …
Effect of methylnaltrexone and naloxone on esophageal motor function in man.
Scarpellini E, Pauwels A, Vos R, Rommel N, Tack J. Scarpellini E, et al. Neurogastroenterol Motil. 2017 Mar;29(3). doi: 10.1111/nmo.12938. Epub 2017 Jan 22. Neurogastroenterol Motil. 2017. PMID: 28110513 Clinical Trial.
BACKGROUND: Endogenous opioids (EO) acting on mu-opiod receptors in central and enteric nervous system (ENS) control gastrointestinal motility but it is still unclear whether EO in ENS may control esophageal function in man, thus we will study the effects of methylnaltrexone (MNT …
BACKGROUND: Endogenous opioids (EO) acting on mu-opiod receptors in central and enteric nervous system (ENS) control gastrointestinal motili …
2,684 results